Chris Brannigan, Chairman of Hope for Hasti, has been selected to attend the acclaimed annual EURORDIS Summer School on Medicines Research & Development training.

The EURORDIS Summer School provides rare disease patient advocates and researchers working with rare diseases with the knowledge and skills needed to become experts in medicines research and development. Topics covered include clinical trials methodology, clinical research, ethics in medicines development and regulatory affairs.

As Hope for Hasti moves inextricably toward creating a gene therapy for CdLS, focus is slowly migrating to the next phase of the project, which is to deliver clinical trials and navigate the regulatory pathway to have the resulting treatment approved for use. As one of the small number of applicants selected to attend this training, this is a rare and unique opportunity to learn from the experts in Europe’s rare disease agency

EURORDIS is a patient-driven alliance of patient organisations representing 949 rare disease patient organisations in 73 countries. They are the voice of 30 million people affected by rare diseases throughout Europe and plays an important role in the orphan drug development process.

This training and the contacts Hope for Hasti can develop as a result will be invaluable in ensuring the success of future treatments for CdLS.